Lactose India Shareholders Approve Vitanosh Ingredients Merger

The shareholder meeting concluded, with results expected by March 30. The merger aims to boost capacity and products, though Vitanosh's net loss and integration risks remain key considerations.

Meeting Details

Lactose (India) Limited held its NCLT-convened meeting of equity shareholders virtually on March 28, 2026. The meeting, lasting 21 minutes from 10:30 AM to 10:51 AM IST, focused on approving the proposed merger between Lactose India and Vitanosh Ingredients Private Limited. Remote e-voting concluded on March 27, 2026. Results will be reported to the NCLT and publicly disclosed by March 30, 2026.

Strategic Significance

This vote is a key step in Lactose India's plan to consolidate operations and expand its business by merging with Vitanosh Ingredients. The merger aims to create a larger, more integrated company with improved manufacturing capacity and a wider product portfolio.

Company Background

Lactose India, established in 1991, is a key manufacturer of pharmaceutical-grade lactose monohydrate and lactulose in India, operating a facility in Vadodara, Gujarat. It holds a significant share of India's lactose market. Vitanosh Ingredients Private Limited, incorporated in 2019, manufactures and trades dairy-based products and ingredients.

Merger Impact

The merger is set to increase Lactose India's manufacturing capacity by 50%, from 10,000 MT to 15,000 MT annually. Following the transaction, the promoter group's shareholding is expected to rise to 58.84% from 53.65%. The combined business anticipates benefits from an expanded product range, including high-margin lactose variants. Lactose India will also assume Vitanosh Ingredients' net loss of ₹1.96 crore from FY2025.

Potential Risks

Vitanosh Ingredients reported a net loss of ₹1.96 crore in FY2025, which Lactose India will absorb post-merger, potentially impacting short-term profitability. Integrating Vitanosh's operations and finances requires careful execution to realize anticipated synergies and avoid disruptions. Lactose India's own performance shows a low return on equity of 9.58% over the last 3 years, and it has not paid dividends, suggesting potential efficiency or cash management concerns.

Industry Peers

Lactose India operates in the pharmaceutical ingredients sector alongside larger entities such as Sun Pharmaceutical Industries Ltd., Divi's Laboratories Ltd., Torrent Pharmaceuticals Ltd., and Lupin Ltd. These competitors often possess greater scale, diversification, and R&D capabilities.

Key Financials

Lactose (India) Limited's net sales increased from ₹34.96 crore in March 2021 to ₹116.40 crore in March 2025. Profit before tax improved from a loss of ₹3.27 crore in March 2021 to a profit of ₹6.92 crore in March 2025. Vitanosh Ingredients generated revenue of ₹36 lakh for the financial year ending March 31, 2024.

Next Steps

Investors will monitor the official announcement of the shareholder vote results by March 30, 2026. Progress on the scheme's submission and approval process with the National Company Law Tribunal (NCLT) will be tracked, along with any further regulatory filings. The company's ability to integrate Vitanosh's operations, manage the absorbed net loss, and successfully launch new products will be key areas to watch.